Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 37, Issue 2, 1997, Pages 247-252

  Laverdière, Jacques ^a   Gomez, José L ^b   Cusan, Leonelo ^b   Suburu, Elbio Raul ^b   Diamond, Pierre ^b   Lemay, Martin ^b   Candas, Bernard ^b   Fortin, André ^b   Labrie, Fernand ^b  

^a LAVAL UNIVERSITY   (Canada)

^b NONE

Author keywords

Neoadjuvant and adjuvant hormonal treatment; Prostate cancer; Radiation therapy

Indexed keywords

ANDROGEN; FLUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; TRANSRECTAL ULTRASONOGRAPHY; TUMOR VOLUME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; COMBINED MODALITY THERAPY; FLUTAMIDE; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030933348     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(96)00513-5     Document Type: Article

References (37)

1. Babaian, R.; Joseph, M. D.; Munekado Kojima, M. D.; Masahito Saitoh, M. D.; Alberto, G.; Ayala, M. D. Detection of residual prostate cancer after external radiotherapy. Role of prostate specific antigen and transrectal ultrasonography. Cancer 75:2153-2158.
2. Bagshaw, M. A.; Cox, R. S.; Ray, G. R. Status of prostate cancer at Stanford University. NCI Monogr. 7:47; 1988.
3. Bagshaw, M. A.; Cox, R. S.; Ray, G. R. Status of radiation treatment of prostate cancer at Stanford University. NCI Monogr. 7:47-60; 1988.
4. Cox, I. D.; Kline, R. W. Do prostatic biopsies 12 months or more after external irradiation for adenocarcinoma, Stage III, Predict long term survival? Int. J. Radiat. Oncol. Biol. Phys. 9:299; 1983.
5. Dugan, T. C.; Shipley, W. U.; Young, R. H.; Verhey, L. J.; Althausen, A. F.; Heney, N. M.; McManus, P. L.; Abranam, E. H. Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: Correlation with original histological grade and current prostate specific antigen levels. J. Urol. 146:1313-1316; 1991.
6. Forman, J. D.; Oppenheim, T.; Liu, H. Frequency of residual neoplasm in the prostate following three-dimensional conformal radiotherapy. Prostate 23:235-243; 1993.
7. Frieha, F. S.; Bagshaw, M. A. Carcinoma of the prostate. Results of post-irradiation biopsy. Prostate 5:19; 1994.
8. Fuks, A.; Leibel, A. A.; Wallner, K. E.; et al. The effect of local control on metastatic dissemination in carcinoma of the prostate. Long term results in patients treated with 1-125 implantation. Int. J. Radiat. Oncol. Biol. Phys. 21:537-547; 1991.
9. Goad, J. R.; Chang, S.-J.; Ohori, M.; Scardino, P. T. PSA after definitive radiotherapy for clinically localized prostate cancer. Urol. Clin. North Am. 20:727-736; 1993.
10. Gunar, K. Zagars: Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J. Urol. 152:1786-1791; 1994.
11. Hanks, G. E. External-beam radiation therapy for clinically localized prostate cancer: Patterns of Care studies in the United States. NCI Monogr. 7:75-84; 1988.
12. Hanks, G. E. Optimizing the radiation treatment and outcome of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 11:1235-1245; 1985.
13. Hanks, G. E.; Asbell, S. O.; Krall, J. M.; Perez, C. A.; Dogett, R. L. S.; Rubin, P.; Sause, W. T.; Pilepich, M. V. Outcome for lymph node negative T1b,2 (A-2,B) prostate cancer treated with external beam radiation therapy in RTOG 77-06. Int. J. Radiat. Oncol. Biol. Phys. 21:1099-1103; 1991.
14. Hanks, G. E.; Asbell, S. O.; Krall, J. M.; Perez, C. A.; Dogett, R. L. S.; Rubin, P.; Sause, W. T.; Pilepich, M. V. Outcome for lymph node negative T1b,2 (A-2,B) prostate cancer treated with external beam radiation therapy in RTOG 77-06. Int. J. Radiat. Oncol. Biol. Phys. 21:1099-1103; 1991.
15. Harisiadis, L.; Veenemar, J.; Senyzsyn, J. A.; et al. Carcinoma of the prostate: treatment with external radiotherapy. Cancer 41:2131-2142; 1978.
16. Kaplan, I. D.; Cox, R. S.; Bagshaw, M. A. PSA after external beam radiotherapy for prostatic cancer: Follow-up. J. Urol 149:519-522; 1993.
17. Krall, J. M.; Owen, J. B.; Hanks, G. E. Long term results of treatment of prostate cancer in the USA in 1973, 1978, and 1983 (Abstract). Int. J. Radiat. Oncol. Biol. Phys. 24(Suppl. 1):147; 1992.
18. Kuban, D. A.; El-Mahdhi, A. M.; Schellhammer, P. F. Effective local tumour control on distant metastases and survival in prostate cancer. J. Urol. 30:420-426; 1987.
19. Kuban, D. A.; El-Mahdi, A. M.; Schelhamer, P. F. Prognostic significance of post-irradiation prostate biopsies. Oncology 7:29-38; 1993.
20. Labrie, F.; Cusan, L.; Gomez, J. L.; Diamond, P.; Suburu, E. R.; Lemay, M.; Têtu, B.; Fradet, Y.; Candas, B. Downstaging of early stage prostate cancer before radical prostatectomy: The first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist (symposium). Urology 44(6A):29-37; 1994.
21. Labrie, F.; Dupont, A.; Cusan, L.; Gomez, J. L.; Diamond, P.; Koutsilieris, M.; Suburu, E. R.; Fradet, Y.; Lemay, M.; Têtu, B.; Emond, J.; Candas, B. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin. Invest. Med. 16:499-509; 1993.
22. Leach, G. E. Radiotherapy for prostatic carcinoma: Post-irradiation prostatic biopsy and recurrence patterns with long-term followup. J. Urol. 128-505; 1982.
23. Leibel, S. A.; Hanks, G. E.; Kramer, S. Patterns of Care outcome studies: Result of the national practice in adenocarcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 10:401; 1984.
24. Perez, C. A.; Hanks, G. E.; Leibel, S. A. Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy. Cancer 72:3156-3173; 1993.
25. Perez, C. A.; Pilepich, M. V.; Garcia, D. Definitive radiation therapy in carcinoma of the prostate localized to the pelvis: Experience at the Malinckrodt Institute of Radiology. NCI Monogr. 7:85-94; 1988.
26. Pilepich, M. V.; Krall, J.; Al-Sarraf, M.; Roach, M., III; Doggett, R. L. S.; Sause, W.; Lawton, C. A.; Abrams, R. A.; Rotman, M.; Rubin, P.; Shipley, W. U.; Cox, J. D. A phase III trial of androgen suppression before and during radiation therapy (RT) for locally advanced prostatic: Preliminary report of RTOG protocol 8610. Proc. Am. Soc. Clin. Oncol. 12:229; March 1993.
27. Pisansky, T. M.; Cha, S. S.; Earle, J. D.; Durr, E. D.; Kozelsky, T. F.; Wieand, S.; Oesterling, J. E. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J. Clin. Oncol. 11:2158-2165; 1993.
28. Porter, A. T.; Venner, P. M. The role of cytoreduction prior to definitive radiotherapy in locally advanced prostate cancer. Prog. Clin. Biol. Res. 359:231-239; 1990.
29. Prestidge, B. R.; Kaplan, I.; Bagshaw, M. A. The clinical significance of a positive post-irradiation prostatic biopsy without distant metastases. Proceedings of the 33nd Annual ASTRO Meeting. Abstract 72. Int. J. Radiat. Oncol. Biol. Phys. 21(S1):152; 1991.
30. Ritter, M. A.; Messing, E. M.; Shanahan, T. G.; Potts, S.; Chappell, R. J.; Kinsella, T. J. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J. Clin. Oncol. 10:1208; 1992.
31. Rosen, E.; Cassady, J. R.; Connolly, J. Radiotherapy for prostate carcinoma: The JCRT Experience: Factors related to tumour control and complications. Int. J. Radiat. Oncol. Biol. Phys. 11:725-730; 1985.
32. Shipley, W. U.; Prout, G. R.; Coachman, N. M.; McManus, P. L.; Healey, E. A.; Althausen, A. F.; Heney, N. M.; Parkhurst, E. C.; Young, H. H., III; Shipley, W.; Kaufman, S. D. Radiation therapy for localized prostate carcinoma: Experience at the Massachusetts General Hospital (1973-1981). NCI Monogr. 7:67-73; 1988.
33. Vaillancourt, L.; Têtu, B.; Fradet, Y.; Dupont, A.; Gomez, J. L.; Cusan, L.; Suburu, E. R.; Diamond, P.; Candas, B.; Labrie, F. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: A randomized study. Am. J. Surg. Pathol. 20:86-93; 1996.
34. Zagars, G. K. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 23:47; 1992.
35. Zagars, G. K. Serum PSA as a tumor marker for patients undergoing definitive radiation therapy. Urol. Clin. North Am. 20:737-747; 1993.
36. Zagars, G. K.; von Eschenbach, A. C. Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiotherapy. Cancer 72:538; 1993.
37. Zagars, G. K.; von Eschenbach, A. C.; Johnson, D. E. Stage-C adenocarcinoma of the prostate: An analysis of 551 patients treated with external beam radiation. Cancer 60:1489-1499; 1987.